Guacatonga has shown to be benificial in killing cancer cells and has a rich history in herbal medicine systems in nearly every tropical country where it grows. The Karaja Indians in Brazil prepare a bark maceration to treat diarrhea; the Shipibo-Conibo Indians of Peru use a decoction of the bark for diarrhea, chest colds and flu. 
 
Some of the active ingredients documented, researched, and verified in Guacatonga are a group of clerodane diterpenes. These phytochemicals are being researched and patented for their active biological properties and potential uses.

For more complete information on this unique rainforest plant, please see plant database file on Guacatonga.

Raintree's guacatonga capsules are sold in bottles of 100 capsules with 600 milligrams per capsule of pure guacatonga ground leaf and stem, rich in active and beneficial phytochemicals which occur naturally in this plant. We use no binders or fillers so the capsules are 100% pure finely milled Guacatonga powder. Raintree's Guacatonga has been sustainably wild harvested (without pesticides or fertilizers) in the Brazilian Amazon rainforest.

Print a FREE Technical Data Report (normally sells for US$20.00!) 

Traditional Uses: For cancer (sarcoma, carcinoma, and adenocarcinoma); for stomach disorders (ulcers, acid reflux, indigestion, dyspepsia, stomachache); as an antivenin for snake, spider and bee bites and stings; as a topical analgesic (pain-reliever) and anti-inflammatory for skin diseases, rashes and wounds; as a blood purifier and for general detoxification

Ingredients: 100% pure guacatonga (Casearia sylvestris) leaf & stem. No binders, fillers or additives are used. This plant is non-irradiated and non-fumigated.

Suggested Use: Take 3 capsules 2-3 times daily or as directed by a healthcare professional.

Contraindications: Not to be used during pregnancy or while breast-feeding.

Drug Interactions: None reported.

Other Observations: None reported. 

Buy 3 - 5 bottles and receive 5% off!
Buy 6  or more bottles and receive 10% off! 

BIOLOGICAL ACTIVITIES AND CLINICAL RESEARCH
The research on guacatonga's anticancerous properties began in 1988 by Japanese researchers from the Tokyo College of Pharmacy and Pharmacognosy. They published one preliminary trial in 1988 on their discovery of these novel clerodane diterpenes and their anticancerous and antitumorous activities. The study indicated that an ethanol extract of the leaf showed strong antitumorous activity in laboratory mice with sarcomas. As soon as they made this discovery, they rushed to patent it, filing a Japanese patent for the casearin chemicals they'd discovered as new antitumorous agents. They published a follow-up study in 1990, again reporting their results from injecting mice with sarcomas with an ethanol extract of guacatonga leaves (100 mg per gram of body weight) and confirming their previous findings. They then tested individual casearins against various human cancer cell lines and published two more studies in 1991 and 1992. These studies reported newly isolated casearin chemicals and their antitumorous and anticancerous actions against various cancer tumor cells. Oddly, the Japanese researchers have not published any further studies and, since they had already filed patents, other research groups have not been forthcoming in funding research dollars on these patented antitumorous plant chemicals.

In 2002, however, a well-known research group in North Carolina discovered three new casearins in the leaves and stems of guacatonga that the Japanese had not (and, obviously, hadn't patented). They named the new chemicals casearvestrin A, B and C, and published their first study in February, 2002, stating: "All three compounds displayed promising bioactivity, both in cytotoxicity assays against a panel of tumor cell lines and in antifungal assays . . ." Their research tested the new plant chemicals against human lung, colon and ovarian tumor cells and indicated all three compounds had toxicity to cancer cells in very small amounts. This research was supported by a grant from the National Cancer Institute, National Institutes of Health (NCI) and performed by a non-profit biotech company, a large pharmaceutical company and a major university.

The NCI has also performed research in-house on clerodane diterpenoids found in another Casearia plant species documenting the antitumor properties of its novel diterpenoids and another university research group has documented the anticancerous properties of this class of chemicals in a Casearia plant from the Madagascar rainforest as well. It will be interesting to see if this diversified group will actually develop these chemicals into new effective chemotherapeutic agents; their research is ongoing.

All other research on the chemicals and activities of guacatonga has been performed by Brazilian research groups over the years. The first published toxicity study with rats indicated no toxicity with an ethanol extract of the leaves at 1840 mg per kg. This research group, at the University of Sao Paulo, studied the anti-ulcer properties of the plant (based on its long history of use as an effective herbal remedy for ulcers). They published two studies confirming these benefits. The first study, with rats (in 1990), showed that a crude leaf extract reduced the volume of gastric secretion by 42%, but had little effect on pH. The extract also prevented lab-induced acute gastric mucosal injury which was equivalent to the antiulcer drug cimetidine (Tagamet?). Ten years later they published a second rat study, documenting that a crude leaf extract protected the stomach lining without changing gastric pH and sped healing of acetic acid-induced chronic ulcers and H. pylori ulcers.

Another Brazilian researcher documented that a bark-and-leaf infusion demonstrated pain relieving and mild anti-inflammatory properties in mice. A university researcher followed up on the anti-inflammatory research, publishing in her dissertation that an extract of the leaves was as effective against inflammation in mice as the NSAID drugs Prioxicam? and Meloxicam?. Leaf extracts have also been shown by two research groups to be active against common food poisoning bacteria strains, Bacillus cerus and B. subtilis, but inactive against such other common bacteria as Staphylococcus, Streptoccoccus, and E. coli.

CURRENT PRACTICAL USES
It will be interesting to see what happens with guacatonga's ongoing cancer research - especially with sarcomas. These types of tumors typically grow very quickly, are resistant to many of the approved cancer drugs, and represent a bleak prognosis for most cancer patients. In the meantime, guacatonga is considered a safe plant and a great natural herbal remedy for ulcers, inflammation, and pain, and will continue to be used as a snakebite remedy throughout the Amazon jungles by the indigenous peoples. Although not widely available in the U.S. market yet, hopefully as more people learn of its beneficial uses, the market demand for it will increase.

Third-Party Published Research
This Raintree product has not been the subject of any clinical research. All available third-party research on guacatonga can be found at PubMed/Medline. A partial listing of the published research on guacatonga is shown below:

Cytotoxic & Anticancerous Actions:
Balunas, M. J., et al. "Relationships between inhibitory activity against a cancer cell line panel, profiles of plants collected, and compound classes isolated in an anticancer drug discovery project." Chem. Biodivers. 2006; 3(8): 897-915.
Shen, Y. C., et al. "Cytotoxic clerodane diterpenoids from Casearia membranacea." J. Nat. Prod. 2005; 68(11): 1665-8.
Maistro, E. L., et al. “Evaluation of the genotoxic potential of the Casearia sylvestris extract on HTC and V79 cells by the comet assay.” Toxicol. In Vitro. 2004 Jun; 18(3): 337-42.
Oberlies, N. H., et al. “Novel bioactive clerodane diterpenoids from the leaves and twigs of Casearia sylvestris.” J. Nat. Prod. 2002; 65(2): 95–99.
Sai Prakash, C. V., et al. “Structure and stereochemistry of new cytotoxic clerodane diterpenoids from the bark of Casearia lucida from the Madagascar rainforest.” J. Nat. Prod. 2002; 65(2): 100-7.
Beutler, J. A. “Novel cytotoxic diterpenes from Casearia arborea.” J. Nat. Prod. 2000; 63(5): 657-61.
Almeida, A. “Antitumor and anti-inflammatory effects of extract from Casearia sylvestris: comparative study with Piroxicam and Meloxicam.” Instituto de Ciencias Biomedicas, University of Sao Paulo (Dissertation, 4/02/99).
Itokawa, H., et al. “Antitumor substances from South American plants.” J. Pharmacobio. Dyn. 1992; 15(1): S-2-.
Morita, H., et al. “Structures and cytotoxic activity relationship of casearins, new clerodane diterpenes from Casearia sylvestris Sw.” Chem. Pharm. Bull. (Tokyo) 1991 Dec; 39(3): 693–97.
Itokawa, H., et al. “New antitumor principles, casearins A–F, for Casearia sylvestris Sw. (Flacourtiaceae).” Chem. Pharm. Bull. (Tokyo) 1990; 38(12): 3384–88.
Itokawa, H., et al. “Isolation of diterpenes as antitumor agents from plants.” Patent—Japan Kokai Tokyo Koho–01 1989; 149, 779: 6pp.
Itokawa, H., et al. “Antitumor principles from Casearia sylvestris Sw. (Flacourtiaceae), structure elucidation of new clerodane diterpenes by 2-D NMR spectroscopy.” Chem. Pharm. Bull. (Tokyo) 1988 March; 36(4): 1585–88.

Antiulcer & Antacid Actions:
Esteves, I., et al. “Gastric antiulcer and anti-inflammatory activities of the essential oil from Casearia sylvestris Sw.” J. Ethnopharmacol. 2005 Oct; 101(1-3): 191-6.
Sertie, J. A., et al. “Antiulcer activity of the crude extract from the leaves of Casearia slyvestris.” Pharmaceutical Biol. 2000; 38(2): 112–19.
Basile, A. C., et al. “Pharmacological assay of Casearia sylvestris. I: Preventive anti-ulcer activity and toxicity of the leaf crude extract.” J. Ethnopharmacol. 1990; 30(2): 185–97.

Neuroprotective Actions:
da Silva, A. C., et al. "Inhibition of NTPDase, 5'-nucleotidase, Na+/K+-ATPase and acetylcholinesterase activities by subchronic treatment with Casearia sylvestris." Phytomedicine. 2006; 13(7): 509-14.

Antivenin Actions:
Raslan, D.S., et al. “Anti-PLA2 action test of Casearia sylvestris Sw.” Boll. Chim. Farm. 2002 Nov-Dec; 141(6): 457-60.
Borges, M., et al. “Neutralization of proteases from Bothrops snake venoms by the aqueous extract from Casearia sylvestris (Flacourtiaceae).” Toxicon 2001; 39(12): 1863–69.
Borges, M., et al. “Effects of aqueous extract of Casearia sylvestris (Flacourtiaceae) on actions of snake and bee venoms and on activity of phospholipases A(2).” Comp. Biochem. Physiol. B. 2000 Sep 1; 127(1): 21–30.
Borges, M., et al. “Partial purification of Casearia sylvestris Sa. extract and its anti-PLA2 Action.” Comp. Biochem. Physiol. Ser. B. 2000; 127b(1): 21–30.
Ruppelt, B. M., et al. “Pharmacological screening of plants recommended by folk medicine as antisnake venom—I. Analgesic and anti-inflammatory activities.” Mem. Inst. Oswaldo Cruz 1991; 86: 203–05.

Anti-inflammatory & Pain-Relieving Actions:
Silva, F.B., et al. “Natural medicaments in endodontics—a comparative study of the anti-inflammatory action.” Pesqui. Odontol. Bras. 2004 Apr-Jun; 18(2): 174-9.
Almeida, A. “Antitumor and anti-inflammatory effects of extract from Casearia sylvestris: comparative study with Piroxicam and Meloxicam.” Instituto de Ciencias Biomedicas, University of Sao Paulo (Dissertation, 4/02/99).

Antimicrobial, Antiparasitic, & Insecticidal Actions:
de Mesquita, M. L.,et al. "In vitro antiplasmodial activity of Brazilian Cerrado plants used as traditional remedies." J. Ethnopharmacol. 2007 Mar; 110(1): 165-70.
Rodrigues, A. M., et al. "Larvicidal activity of some Cerrado plant extracts against Aedes aegypti." J. Am. Mosq. Control Assoc. 2006 Jun; 22(2): 314-7.
Mesquita, M.L., et al. “Antileishmanial and trypanocidal activity of Brazilian Cerrado plants.” Mem. Inst. Oswaldo Cruz. 2005 Nov; 100(7): 783-7.
Espindola, L. S., et al. “Trypanocidal activity of a new diterpene from Casearia sylvestris var. lingua.” Planta Med. 2004; 70(11): 1093-5.
de Almeida Alves, T. M. “Biological screening of Brazilian medicinal plants.” Mem. Inst. Oswaldo Cruz. 2000 May/Jun; 95(3): 367–73.
Chiappeta, A. D., et al. “Higher plants with biological activity—plants of Pernambuco. I.” Rev. Inst. Antibiot. 1983; 21(1/2): 43–50.